Delcath(DCTH) - 2023 Q4 - Annual Results

Exhibit 99.1 Delcath Systems Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update Increases 2024 Treatment Site Activation Guidance to 20 Sites QUEENSBURY – March 26, 2024, Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023. Recent Busin ...